Condition Directory

Long COVID clinical trials

Directory of U.S. ClinicalTrials.gov public records for Long COVID. Browse Long COVID recruiting trials, filter by phase, sponsor, location, or intervention, and open the official ClinicalTrials.gov study record for each result.

By the Clinical Trials Finder editorial team Guidance last reviewed June 10, 2026 Data synced September 6, 2026 Report an issue

ClinicalTrials.gov public records Last synced Sep 6, 2026, 1:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

Shown on this page

Current sort

How Long COVID studies are organized in the registry

Terminology for this condition is unusually inconsistent across the registry: the same kind of study may be filed under “long COVID,” “post-acute sequelae of SARS-CoV-2,” the abbreviation PASC, or “post-COVID conditions.” Trying more than one of these terms is the single most effective way to avoid missing records.

Terms that often appear in related listings

PASC post-acute sequelae post-COVID long haul COVID

These describe how studies tend to be titled and grouped on ClinicalTrials.gov — they are search vocabulary, not medical guidance.

Showing 1–12 of 79 matching trials for Long COVID.

Live ClinicalTrials.gov results.

Active filters: "PASC" Clear condition filters

Local aggregate panels are hidden while filters are applied so the page stays focused on the filtered live results.

Live official records

Open in full search

Conditions: Post-Acute COVID-19 Syndrome
Interventions: Keytruda; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Long COVID, Long Covid19, Post-Acute COVID-19, Post-Acute COVID-19 Syndrome, Post-Acute COVID-19 Infection, COVID Long-Haul
Interventions: Structured mindfulness intervention; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Systemic Inflammation, Neuroinflammation, Microvascular Thrombosis
Interventions: IV normal saline, IV immunoglobulin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: SARS CoV-2 Post-Acute Sequelae
Interventions: This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms.; Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 75 Years
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Long COVID, Post Acute Sequelae of COVID-19
Interventions: 11C-PS13; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: PASC Post Acute Sequelae of COVID-19
Interventions: Not listed
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: BrainHQ/Active Comparator Activity, BrainHQ, PASC CoRE, tDCS-active, tDCS-sham; Other · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Long COVID, Long Covid19, Long Covid-19
Interventions: IVIG + Coordinated Care, IVIG Placebo + Coordinated Care, Ivabradine + Coordinated Care, Ivabradine Placebo + Coordinated Care, IVIG + Usual Care, IVIG Placebo + Usual Care, Ivabradine + Usual Care, Ivabradine Placebo + Usual Care; Drug
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 50
States / cities: Opelika, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 45 more

Conditions: Long COVID, Chronic Fatigue Syndrome
Interventions: Transcutaneous vagus nerve stimulator; Device
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Long COVID, Long Coronavirus Disease 2019 (Covid19), Long Covid-19
Interventions: IVIG (intravenous immunoglobulin), IVIG Placebo, Coordinated Care, Usual Care; Drug · Behavioral
Lead sponsor: Kanecia Obie Zimmerman; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Post Acute COVID-19 Syndrome
Interventions: Immulina TM, Placebo; Drug · Dietary Supplement
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: 18 Years to 99 Years
Enrollment: 101 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 8
States / cities: Honolulu, Hawaii • Baton Rouge, Louisiana • New Orleans, Louisiana + 5 more

Conditions: Dysexecutive Syndrome, Post-Acute Sequelae of COVID-19
Interventions: Active tDCS, Sham tDCS; Device
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Charlestown, Massachusetts

About this Long COVID clinical trials directory page

What this page lists: U.S. ClinicalTrials.gov public records that list Long COVID as a study condition, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
How to narrow results: Use the filters above to scope by intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Long COVID.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Long COVID clinical trials

How Long COVID studies are organized in the registry

Filter and sort this condition

Live official records

Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)

Long-Covid-19 Alleviation Through Learning Mindfulness Study

Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2

Long-Term Study of COVID-19 Infection and Long COVID

PET Imaging of Cyclooxygenase-1 in Participants With Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)

Cross-Sectional Evaluation of Persistence of SARS-CoV-2 Remnants After Recovery From Acute Infection

RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms

RECOVER-AUTONOMIC Platform Protocol

tVNS in Long COVID-19

RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)

Effects of Immulina TM Supplements With PASC Patients

Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)

About this Long COVID clinical trials directory page